Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KetaBio
- Ownership
- Private
- Development stage
- Other
01
Overview
KetaBio is an early-stage biotechnology company focused on the development of novel ketamine-based therapeutics for psychiatric and neurological conditions. The company leverages the established efficacy of ketamine in treating treatment-resistant depression and aims to optimize its delivery and safety profile through proprietary formulations. KetaBio's research primarily targets the N-methyl-D-aspartate (NMDA) receptor to provide rapid-acting relief for patients suffering from severe mood disorders and chronic pain. By exploring diverse routes of administration, the company seeks to improve patient access and clinical outcomes in the mental health space.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on KetaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KetaBio.